MeSH term
Frequency | Condition_Probility | Adult | 21 | 0.0 |
Humans | 80 | 0.0 |
Male | 26 | 0.0 |
Middle Aged | 21 | 0.0 |
Cytoskeletal Proteins/*genetics/metabolism | 7 | 33.0 |
Gene Deletion | 3 | 0.0 |
Gene Expression Regulation, Neoplastic | 7 | 0.0 |
Genes, APC | 8 | 9.0 |
Heterozygote | 5 | 0.0 |
Introns | 2 | 0.0 |
Recombinant Proteins/metabolism | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 51 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 19 | 0.0 |
*Trans-Activators | 45 | 7.0 |
Transcription, Genetic | 5 | 0.0 |
Transfection | 5 | 0.0 |
Tumor Cells, Cultured | 15 | 0.0 |
Alleles | 3 | 0.0 |
Base Sequence | 20 | 0.0 |
Codon | 6 | 1.0 |
Exons | 11 | 0.0 |
Homozygote | 2 | 0.0 |
Loss of Heterozygosity | 4 | 0.0 |
Microsatellite Repeats/genetics | 3 | 0.0 |
Microscopy, Fluorescence | 3 | 0.0 |
Molecular Sequence Data | 18 | 0.0 |
Mutation | 14 | 0.0 |
Polymorphism, Genetic | 3 | 0.0 |
DNA Mutational Analysis | 25 | 0.0 |
DNA, Neoplasm/chemistry/genetics | 2 | 1.0 |
Disease Progression | 3 | 0.0 |
Exons/*genetics | 2 | 0.0 |
Immunohistochemistry | 15 | 0.0 |
Cytoskeletal Proteins/*genetics | 31 | 28.0 |
DNA, Neoplasm/genetics | 7 | 0.0 |
Exons/genetics | 5 | 0.0 |
Melanoma/*genetics/metabolism/pathology | 2 | 12.0 |
Mutation/*genetics | 6 | 0.0 |
Polymorphism, Single-Stranded Conformational | 15 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 6 | 0.0 |
Animals | 13 | 0.0 |
*Genes, APC | 9 | 11.0 |
Mice | 8 | 0.0 |
Signal Transduction/genetics | 4 | 1.0 |
beta-Transducin Repeat-Containing Proteins | 2 | 16.0 |
Amino Acid Sequence | 10 | 0.0 |
Liver Neoplasms, Experimental/chemically induced/*genetics | 2 | 100.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
Rats | 5 | 0.0 |
Rats, Inbred F344 | 5 | 1.0 |
Sequence Analysis, DNA | 7 | 0.0 |
Female | 30 | 0.0 |
Pedigree | 3 | 0.0 |
Aged | 13 | 0.0 |
Carcinoma, Endometrioid/*genetics/metabolism/pathology | 2 | 66.0 |
Cell Nucleus/metabolism | 5 | 0.0 |
Cytoskeletal Proteins/biosynthesis/*genetics | 2 | 22.0 |
*Gene Expression Regulation, Neoplastic | 8 | 0.0 |
Neoplasm Staging | 4 | 0.0 |
Proteins/genetics | 2 | 0.0 |
*Repressor Proteins | 5 | 0.0 |
Adolescent | 6 | 0.0 |
Child | 6 | 0.0 |
Child, Preschool | 4 | 0.0 |
Infant | 4 | 0.0 |
Medulloblastoma/*genetics | 2 | 9.0 |
Proteins/*genetics | 2 | 0.0 |
*Zebrafish Proteins | 11 | 4.0 |
HT29 Cells | 2 | 1.0 |
Signal Transduction | 6 | 0.0 |
*Transcription, Genetic | 2 | 0.0 |
DNA Primers/chemistry | 5 | 0.0 |
DNA, Neoplasm/analysis | 3 | 0.0 |
Hair Diseases/*genetics/pathology | 2 | 28.0 |
*Mutation | 13 | 0.0 |
Pilomatrixoma/*genetics/pathology | 2 | 100.0 |
Polymerase Chain Reaction | 12 | 0.0 |
Skin Neoplasms/*genetics/pathology | 2 | 3.0 |
*Chromosomes, Human, Pair 3 | 5 | 1.0 |
Gene Rearrangement | 2 | 0.0 |
Aged, 80 and over | 6 | 0.0 |
Transcription Factors/genetics | 2 | 0.0 |
Adenomatous Polyposis Coli Protein | 5 | 6.0 |
Amino Acid Substitution | 4 | 0.0 |
Blotting, Western | 4 | 0.0 |
Cytoskeletal Proteins/*genetics/*metabolism | 2 | 28.0 |
Gene Frequency | 3 | 0.0 |
Proto-Oncogene Proteins/*physiology | 2 | 0.0 |
*Signal Transduction | 4 | 0.0 |
Genes, p53/genetics | 3 | 1.0 |
Melanoma/*genetics/metabolism | 3 | 21.0 |
CpG Islands/genetics | 2 | 1.0 |
*DNA Methylation | 2 | 0.0 |
Gene Expression Profiling | 2 | 0.0 |
Cell Division | 2 | 0.0 |
Down-Regulation | 2 | 0.0 |
Phenotype | 4 | 0.0 |
Point Mutation | 6 | 0.0 |
Prognosis | 3 | 0.0 |
Cadherins/genetics | 4 | 7.0 |
Colorectal Neoplasms/*genetics/pathology | 2 | 2.0 |
Microsatellite Repeats/*genetics | 3 | 1.0 |
Retrospective Studies | 2 | 0.0 |
Adenomatous Polyposis Coli/*genetics | 2 | 3.0 |
Cell Cycle Proteins/genetics | 2 | 2.0 |
Codon/genetics | 4 | 1.0 |
Cytoskeletal Proteins/genetics | 5 | 8.0 |
Repressor Proteins/genetics | 3 | 2.0 |
Trans-Activators/genetics | 4 | 1.0 |
Glycogen Synthase Kinase 3 | 2 | 2.0 |
Proto-Oncogene Proteins/*genetics | 2 | 0.0 |
Mutation, Missense | 2 | 0.0 |
Binding Sites | 3 | 0.0 |
COS Cells | 2 | 0.0 |
L Cells (Cell Line) | 2 | 0.0 |
Promoter Regions (Genetics) | 3 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Transcription Factors/metabolism | 2 | 0.0 |
*Mutation, Missense | 2 | 0.0 |
Adenoma/chemically induced/genetics | 2 | 66.0 |
Phosphorylation | 2 | 0.0 |
Adenocarcinoma/*genetics | 3 | 2.0 |
Colonic Neoplasms/*genetics | 3 | 3.0 |
Comparative Study | 8 | 0.0 |
Endometrial Neoplasms/*genetics | 2 | 4.0 |
*Point Mutation | 2 | 0.0 |
Alternative Splicing | 2 | 0.0 |
Cell Line, Tumor | 4 | 0.0 |
Sequence Alignment | 3 | 0.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Species Specificity | 2 | 0.0 |
Blotting, Northern | 2 | 0.0 |
*Chromosome Aberrations | 2 | 0.0 |
*Chromosomes, Human, Pair 8 | 2 | 0.0 |
DNA-Binding Proteins/*genetics | 3 | 0.0 |
Cytoskeletal Proteins/*metabolism | 2 | 1.0 |
Neoplasm Proteins/*genetics | 2 | 0.0 |
Adenomatous Polyposis Coli Protein/*genetics | 4 | 44.0 |
Cells, Cultured | 3 | 0.0 |
DNA Methylation | 2 | 0.0 |
Luciferases/metabolism | 2 | 0.0 |
Sequence Deletion | 2 | 0.0 |
Variation (Genetics) | 2 | 0.0 |
Cell Transformation, Neoplastic | 2 | 0.0 |
Ovarian Neoplasms/*genetics | 2 | 0.0 |
Adenoma/*genetics | 3 | 3.0 |
In Situ Hybridization, Fluorescence | 3 | 0.0 |
*Promoter Regions (Genetics) | 3 | 0.0 |
RNA, Messenger/genetics | 4 | 0.0 |
Up-Regulation | 3 | 0.0 |
Colorectal Neoplasms/*genetics | 3 | 1.0 |
Cell Line | 2 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Cytoskeletal Proteins/metabolism | 3 | 1.0 |
Trans-Activators/metabolism | 3 | 0.0 |
Promoter Regions (Genetics)/genetics | 3 | 0.0 |
Proto-Oncogene Proteins/*metabolism | 4 | 0.0 |
Apoptosis/physiology | 2 | 0.0 |
In Situ Nick-End Labeling | 2 | 0.0 |
Chromosome Mapping | 4 | 0.0 |
Neoplasms/*genetics | 2 | 0.0 |
Genes, ras/genetics | 3 | 2.0 |
Trans-Activators/*genetics | 8 | 2.0 |
5' Flanking Region | 2 | 3.0 |
*Chromosomes, Human, Pair 11 | 2 | 0.0 |
Microsatellite Repeats | 2 | 0.0 |
Models, Genetic | 2 | 0.0 |
Proto-Oncogene Proteins/genetics | 2 | 0.0 |
Mutation/genetics | 2 | 0.0 |
